{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T21:53:44Z","timestamp":1757541224923,"version":"3.41.2"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The purpose of this study was to build nomograms for predicting the survival of individual advanced pleural mesothelioma (MPM) patients using the Surveillance, Epidemiology, and End Results (SEER) database.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The 1251 patients enrolled from the SEER database were randomized (in a 7:3 ratio) to a training cohort and an internal validation cohort. Eighty patients were enrolled from the Harbin Medical University Cancer Hospital as the external validation cohort. Nomograms were constructed from variables screened by univariate or multivariate Cox regression analyses and evaluated by consistency indices (C-index), calibration plots, and receiver operating characteristic (ROC) curves. Patients from the SEER database who received chemotherapy alone and chemoradiotherapy were statistically paired using propensity score matching of the two groups and performed subgroup analysis in the screened variables.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The nomograms are well-structured and well-validated prognostic maps constructed from four variables: gender, histology, AJCC stage, and treatment. All individuals were allocated into high-risk versus low-risk groups based on the median risk score of the training cohort, with the high-risk group having worse OS and CSS in all three cohorts (<jats:italic>P<\/jats:italic>&amp;lt;0.05). The outcomes of the subgroup analysis indicated that the advanced MPM patients receiving chemotherapy with or without local radiotherapy do not affect OS or CSS.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The accurate nomograms to predict the survival of patients with advanced MPM were built and validated based on an analysis of the SEER database with an external validation cohort. The study suggests that the additional local radiotherapy to chemotherapy does not increase the survival benefit of patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2023.1139222","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:39:12Z","timestamp":1681450752000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Establishment and validation of nomograms to predict survival probability of advanced malignant pleural mesothelioma based on the SEER database and a Chinese medical institution"],"prefix":"10.3389","volume":"14","author":[{"given":"Xuemei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lele","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingying","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0b013e328302851d","article-title":"Malignant mesothelioma 2008","volume":"14","author":"Zervos","year":"2008","journal-title":"Curr Opin Pulm Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21572","article-title":"Mesothelioma: Scientific clues for prevention, diagnosis, and therapy","volume":"69","author":"Carbone","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0122","article-title":"Current issues in malignant pleural mesothelioma evaluation and management","volume":"19","author":"Ai","year":"2014","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/LCTT.S192558","article-title":"Pain management in patients with malignant mesothelioma: challenges and solutions","volume":"10","author":"Saunders","year":"2019","journal-title":"Lung Cancer (Auckl)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.20517\/2394-4722.2022.78","article-title":"Immunotherapy in malignant pleural mesothelioma: a long story ended in success","volume":"8","author":"Bongiovanni","year":"2022","journal-title":"J Cancer Metastasis Treat"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30459-X","article-title":"Radiotherapy for the treatment of malignant pleural mesothelioma","volume":"18","author":"de Perrot","year":"2017","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw570","article-title":"Characterizing CD137 upregulation on NK cells in patients receiving monoclonal antibody therapy","volume":"28","author":"Makkouk","year":"2017","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jare.2020.02.005","article-title":"Development and validation of a nomogram for predicting late-onset sepsis in preterm infants on the basis of thyroid function and other risk factors: Mixed retrospective and prospective cohort study","volume":"24","author":"Huang","year":"2020","journal-title":"J Adv Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.19","article-title":"A nomogram predicting pulmonary metastasis of hepatocellular carcinoma following partial hepatectomy","volume":"110","author":"Li","year":"2014","journal-title":"Br J Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1235","article-title":"Therapeutic inhibition of the MDM2-p53 interaction prevents recurrence of adenoid cystic carcinomas","volume":"23","author":"N\u00f6r","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/cam4.4458","article-title":"Construction and validation of a prognostic nomogram for anal squamous cell carcinoma","volume":"11","author":"Yang","year":"2022","journal-title":"Cancer Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1027149","article-title":"Establishment of predictive nomogram and web-based survival risk calculator for malignant pleural mesothelioma: A SEER database analysis","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.05.032","article-title":"Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A surveillance, epidemiology, and end results (SEER) study","volume":"146","author":"Thompson","year":"2020","journal-title":"Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1122","article-title":"Neonates with cancer and causes of death; lessons from 615 cases in the SEER databases","volume":"6","author":"Alfaar","year":"2017","journal-title":"Cancer Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4151","article-title":"Development and validation of prognostic nomogram in ependymoma: A retrospective analysis of the SEER database","volume":"10","author":"Jia","year":"2021","journal-title":"Cancer Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.21037\/atm-20-6201","article-title":"Development and validation of a novel nomogram to predict cancer-specific survival in patients with uterine cervical adenocarcinoma","volume":"9","author":"Ni","year":"2021","journal-title":"Ann Transl Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2018.04.09","article-title":"Breath analysis as a diagnostic and screening tool for malignant pleural mesothelioma: a systematic review","volume":"7","author":"Brusselmans","year":"2018","journal-title":"Transl Lung Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.jtho.2017.02.026","article-title":"Improved outcomes with modern lung-sparing trimodality therapy in patients with malignant pleural mesothelioma","volume":"12","author":"Shaikh","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr.2020.03.38","article-title":"Clinical significance of histologic subtyping of malignant pleural mesothelioma","volume":"9","author":"Brcic","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.3190","article-title":"Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"102250","DOI":"10.1016\/j.ctrv.2021.102250","article-title":"Immune checkpoint inhibitors a new player in the therapeutic game of mesothelioma: New reality with new challenges","volume":"99","author":"Parikh","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(89)90266-6","article-title":"Radiation sensitivity of human lung cancer cell lines","volume":"25","author":"Carmichael","year":"1989","journal-title":"Eur J Cancer Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(98)00409-X","article-title":"Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura\u2013a single-institution experience with 189 patients","volume":"43","author":"de Graaf-Strukowska","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2020.11.022","article-title":"Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma","volume":"152","author":"Ghirardelli","year":"2021","journal-title":"Lung Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1183\/09031936.93.04010076","article-title":"Radiographic chest assessment of lung injury following hemithorax irradiation for pleural mesothelioma","volume":"4","author":"Maasilta","year":"1991","journal-title":"Eur Respir J"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.0720","article-title":"Bayesian Adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-Small-Cell lung cancer","volume":"36","author":"Liao","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1139222\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T05:39:15Z","timestamp":1681450755000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1139222\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":28,"alternative-id":["10.3389\/fendo.2023.1139222"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1139222","relation":{},"ISSN":["1664-2392"],"issn-type":[{"type":"electronic","value":"1664-2392"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"article-number":"1139222"}}